Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vestibular Disorders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28 result(s) found for: Vestibular Disorders. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-005484-32 Sponsor Protocol Number: VN-FT-01 Start Date*: 2015-05-28
    Sponsor Name:Lund University
    Full Title: Double-blind, randomized placebo controlled study on the effect from cortisone treatment of vestibular neuritis - function, subjective well-being and stress
    Medical condition: Acute vestibular syndrome better known as Vestibular neuritis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004863 10047392 Vestibular nerve damage LLT
    17.1 100000004854 10047388 Vestibular function disorder LLT
    17.1 100000004862 10051781 Vestibular paralysis LLT
    17.1 100000004854 10013285 Disorder vestibular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023099-13 Sponsor Protocol Number: V00251 ST 201 1A Start Date*: 2011-01-31
    Sponsor Name:PIERRE FABRE MEDICAMENT -IRPF- PIERRE FABRE INNOVATION
    Full Title: V0251 oral suspension efficacy and tolerance in vestibular neuritis. A randomised double-blind placebo controlled study
    Medical condition: The aim of this exploratory study is to assess the efficacy of the L-enantiomer V0251 oral form in the treatment of acute episodes of vertigo.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10047393 Vestibular neuronitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013702-14 Sponsor Protocol Number: BETNV009 Start Date*: 2010-08-13
    Sponsor Name:Hospital of the University of Munich
    Full Title: Effects of betahistine on central vestibular compensation in acute unilateral vestibular failure: a double-blind, placebo-controlled trial
    Medical condition: vestibular failure (vestibular neuritis)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10013993 - Ear and labyrinth disorders 10047386 Vestibular disorder PT
    18.0 10029205 - Nervous system disorders 10029240 Neuritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000388-15 Sponsor Protocol Number: VesPa Start Date*: 2016-08-31
    Sponsor Name:University of the University of Munich
    Full Title: Prophylactic treatment of vestibular paroxysmia with carbamazepine: a prospective, randomized, placebo-controlled, cross-over, multi-center trial
    Medical condition: The main symptoms of vestibular paroxysmia are brief attacks of rotatory or postural vertigo lasting seconds to a few minutes with or without ear symptoms (tinnitus and hypoacusis). As in trigemina...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005054-23 Sponsor Protocol Number: V00251 IV 201 Start Date*: 2007-12-07
    Sponsor Name:PIERRE FABRE MEDICAMENT - IRPF
    Full Title: A double-blind placebo controlled study of 1g, 2g and 4g V0251 efficacy and tolerance in vestibular neuritis.
    Medical condition: V0251 is a new investigational antivertiginous agent which is being developed for the treatment of symptomatic vertiginous crisis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047340 Vertigo LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) ES (Completed) DE (Completed) IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-013701-34 Sponsor Protocol Number: VMMET009 Start Date*: 2011-09-01
    Sponsor Name:Hospital of the University of Munich
    Full Title: Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo- controlled trial
    Medical condition: vestibular migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005770-26 Sponsor Protocol Number: KRONF2 Start Date*: 2023-10-20
    Sponsor Name:Medical University of Warsaw
    Full Title: Phase 2a non-commercial and non-randomized intervention study evaluating the efficacy of crizotinib in the treatment of children with severe type 2 neurofibromatosis, in particular those excluded f...
    Medical condition: Neurofibromatosis type 2 is a genetically determined primary malignancy resulting from a mutation that disables the function of the cell division control gene and leads to neoplasia such as benign ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000523 Acoustic neuroma PT
    27.0 10010331 - Congenital, familial and genetic disorders 10029271 Neurofibromatosis, type 2 (acoustic neurofibromatosis) LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004025-27 Sponsor Protocol Number: Antivert1-B09_PE_V1.0 Start Date*: 2013-02-15
    Sponsor Name:HENNIG ARZNEIMITTEL GmbH & Co. KG
    Full Title: Efficacy and safety of a fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg vs betahistine dihydrochloride 16 mg in patients with vertigo of peripheral origin. A multi-centre, double-b...
    Medical condition: Vertigo of peripheral origin
    Disease: Version SOC Term Classification Code Term Level
    15.0 10013993 - Ear and labyrinth disorders 10031615 Other and unspecified peripheral vertigo LLT
    14.1 10013993 - Ear and labyrinth disorders 10058708 Rotatory vertigo LLT
    14.1 10013993 - Ear and labyrinth disorders 10047344 Vertigo labyrinthine PT
    14.1 10013993 - Ear and labyrinth disorders 10034641 Peripheral vertigo, unspecified LLT
    15.0 10013993 - Ear and labyrinth disorders 10032379 Other peripheral vertigo LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-000562-21 Sponsor Protocol Number: L00014 CP 201 Start Date*: 2007-09-19
    Sponsor Name:PIERRE FABRE MEDICAMENT - IDPF
    Full Title: Effects of TANGANIL (three 500 mg tablets twice daily) on postural disturbances in the elderly.
    Medical condition: Postural disturbances in the elderly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049848 Balance disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-001682-41 Sponsor Protocol Number: HLS03/2011 Start Date*: 2011-05-09
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Comparison of the efficacy and the safety of different schedules of administration of sub-lingual immunotherapy in patients with ragweed pollinosis: a phase III randomized and controlled clinical s...
    Medical condition: Subjects who are allergic to Ragweed.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004803-78 Sponsor Protocol Number: 1.1 Start Date*: 2009-03-20
    Sponsor Name:Imperial College London
    Full Title: Effectiveness of Transtympanic Steroids in unilateral Ménière's disease: a Randomised Controlled Double-Blind Trial
    Medical condition: refractory unilateral Meniere's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000641 Active Meniere's disease, cochleovestibular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003395-72 Sponsor Protocol Number: VitD@BPPV Start Date*: 2016-11-29
    Sponsor Name:Hospital of the University of Munich
    Full Title: Vitamin D in secondary prevention of benign paroxysmal positional vertigo: a prospective, multicenter, randomized, placebo-controlled, double-blind study (VitD@BPPV)
    Medical condition: The main symptoms of Benign Paroxysmal Positional Vertigo (BPPV) are brief, in part strong attacks of rotatory vertigo lasting seconds. These attacks can be provoked by reclination of the head or t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003412-23 Sponsor Protocol Number: V00251IV2024A Start Date*: 2012-01-25
    Sponsor Name:Pierre Fabre Médicament - IRPF
    Full Title: EFFECT OF V0251 IN ACUTE VERTIGO. A RANDOMISED DOUBLE-BLIND PLACEBO CONTROLLED STUDY.
    Medical condition: V0251 is a new antivertiginous agent which is being developed for the treatment of symptomatic vertiginous crisis.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10013993 - Ear and labyrinth disorders 10047340 Vertigo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) ES (Completed) DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-000316-15 Sponsor Protocol Number: 523079.01.114 Start Date*: 2016-09-17
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Clinical Trial to Explore Treatment Effects of Ginkgo biloba Extract EGb 761® in Patients with Different Types of Vertigo and Effect Modification by Type of Vertigo, Chronicity and Concomitant Path...
    Medical condition: Different types of vertigo
    Disease: Version SOC Term Classification Code Term Level
    20.0 10013993 - Ear and labyrinth disorders 10047340 Vertigo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-000752-32 Sponsor Protocol Number: 04T-617 Start Date*: 2006-01-23
    Sponsor Name:Klinikum Grosshadern
    Full Title: Medical treatment of Menière’s disease with betahistine: a placebo-controlled, dose-finding study
    Medical condition: Ménière’s disease is a disorder of the inner ear membranous labyrinth characterized by paroxysmal vertiginous attacks, fluctuating sensorineural hearing loss, aural fullness, and tinnitus .The unde...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027183 Meniere's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001697-42 Sponsor Protocol Number: OML-III-A Start Date*: 2017-08-30
    Sponsor Name:Schülke & Mayr GmbH
    Full Title: Randomized, placebo-controlled, parallel group, double-blind, multi-center Phase III study to assess the inhibition of plaque formation of 0.1% octenidine mouthwash vs placebo in subjects with a gi...
    Medical condition: inhibition of plaque formation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10056984 Dental plaque PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001698-18 Sponsor Protocol Number: OML-III-B Start Date*: 2017-11-06
    Sponsor Name:Schülke & Mayr GmbH
    Full Title: Randomized, placebo-controlled, parallel group, double-blind, multi-center Phase III study to assess the inhibition of plaque formation of 0.1% octenidine mouthwash vs placebo in subjects with a gi...
    Medical condition: inhibition of plaque formation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10056984 Dental plaque PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002728-19 Sponsor Protocol Number: PQ-421a-004 Start Date*: Information not available in EudraCT
    Sponsor Name:ProQR Therapeutics IV B.V.
    Full Title: A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of t...
    Medical condition: Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) NO (Prematurely Ended) DK (Completed) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001545-25 Sponsor Protocol Number: CHDR1409 Start Date*: 2014-07-02
    Sponsor Name:Centre for Human Drug Research
    Full Title: Randomized, double-blind, placebo-controlled, three way crossover, double dummy, single centre study evaluating the effect of haloperidol 2 mg and lorazepam 1 mg on posturography and underlying sys...
    Medical condition: Healthy volunteers (balance disorders)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10049848 Balance disorder PT
    17.0 10029205 - Nervous system disorders 10004070 Balance difficulty LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002729-74 Sponsor Protocol Number: PQ-421a-003 Start Date*: Information not available in EudraCT
    Sponsor Name:ProQR Therapeutics IV B.V.
    Full Title: A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of t...
    Medical condition: Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NO (Completed) DK (Completed) NL (Ongoing) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 08:12:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA